Share This Page
Drug Price Trends for NDC 16714-0190
✉ Email this page to a colleague
Average Pharmacy Cost for 16714-0190
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| GUANFACINE HCL ER 1 MG TABLET | 16714-0190-01 | 0.16924 | EACH | 2025-09-17 |
| GUANFACINE HCL ER 1 MG TABLET | 16714-0190-01 | 0.16979 | EACH | 2025-08-20 |
| GUANFACINE HCL ER 1 MG TABLET | 16714-0190-01 | 0.16889 | EACH | 2025-07-23 |
| GUANFACINE HCL ER 1 MG TABLET | 16714-0190-01 | 0.17716 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 16714-0190
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 16714-0190
Introduction
The pharmaceutical landscape continually evolves as new drugs enter the market, driven by advancements in medical science, unmet clinical needs, and regulatory approval processes. NDC: 16714-0190 refers to a specific drug listed under the National Drug Code system, which uniquely identifies drug products in the United States. Accurate market analysis for this product necessitates understanding its therapeutic indications, competitive environment, regulatory status, manufacturing considerations, and pricing dynamics. This report offers a comprehensive overview, strategic insights, and price projections based on current market conditions and emerging trends.
Product Profile and Therapeutic Landscape
Identification and Therapeutic Indication
NDC: 16714-0190 corresponds to [Insert specific drug name], a [indicate drug class, e.g., biologic, small molecule, biosimilar] indicated primarily for [list approved indications, e.g., treatment of [disease/condition], oncology, autoimmune disorders]. Its mechanism of action involves [briefly describe mechanism], offering potential benefits such as [e.g., improved efficacy, reduced side effects, convenience].
Regulatory Status
The drug has received [FDA approval/accelerated approval/ANDA approval, etc.] from the U.S. Food and Drug Administration (FDA), with regulatory milestones impacting market entry timing. For biologics or specialty drugs, approval pathways and expedited designations further influence market dynamics.
Market Dynamics and Competitive Environment
Current Market Size
The targeted therapeutic area has witnessed a growing patient population, driven by increased disease prevalence and earlier diagnosis. For example, in [year], the global market for [disease/condition] was valued at approximately $X billion and is projected to grow at X% CAGR over the next 5-7 years.[1] Locally, the U.S. is a significant market, accounting for approximately X% of global sales, valued at $X billion as of [latest year].
Competitive Landscape
NDC: 16714-0190 faces competition from [list major competitors or biosimilars if applicable]. The presence of biosimilars or patent expirations can significantly influence price and market share. Patent exclusivity, orphan drug status, or unique delivery mechanisms also delineate competitive advantages.
Market Entry Barriers
Barriers include regulatory approval timelines, reimbursement complexities, manufacturing scalability, and market penetration challenges. Pricing negotiations with payers and formulary inclusion remain pivotal gates for market access.
Pricing Environment and Reimbursement
Current Pricing Strategies
The initial launch price for drugs of similar profile generally falls within the $X to $Y range, contingent on factors like manufacturing costs, therapeutic value, and market competition. For biologics, prices tend to be premium, often exceeding $50,000 annually per patient, reflecting R&D and manufacturing expenses.
Reimbursement Landscape
Medicare, Medicaid, and private insurers influence net pricing through formulary placement and negotiated discounts. Biosimilars and patent cliffs exert downward pressure on prices, encouraging manufacturers to adopt value-based pricing models, discounts, or patient assistance programs to maintain competitiveness.
Pricing Trends
Monitoring recent trends reveals a move towards value-based arrangements, with some manufacturers exploring outcomes-based contracts. Such models can stabilize revenue streams while aligning prices with clinical benefits.
Forecasted Price Projections (2023-2028)
Methodology
Price projections incorporate current list prices, anticipated biosimilar entries, patent expirations, regulatory modifications, and market uptake rates. Market penetration estimates are informed by clinical trial data, physician prescribing behaviors, and payer negotiations.
| Year | Estimated Average Wholesale Price (AWP) | Key Influencing Factors |
|---|---|---|
| 2023 | $X,XXX | Launch phase, initial uptake, limited biosimilar competition |
| 2024 | $X,XXX - $X,XXX | Entry of biosimilars, increasing market competition |
| 2025 | $X,XXX - $X,XXX | Expanded biosimilar adoption, reimbursement adjustments |
| 2026 | $X,XXX - $X,XXX | Further biosimilar proliferation, cost containment policies |
| 2027 | $X,XXX - $X,XXX | Market stabilization, patent expiry effects |
| 2028 | $X,XXX - $X,XXX | Mature market, price normalization |
Note: Actual prices depend on regional factors, individual payer contracts, and the competitive pace of biosimilar entry.
Potential Price Reductions
Biosimilar entry could reduce originator biologic prices by 15-30%, comparable to patterns seen with other biologics such as [example biosimilars, e.g., Humira, Enbrel]. The timing of biosimilar approvals and market acceptance plays a crucial role in determining the extent and speed of these reductions.
Key Market Drivers and Risks
- Innovation and Clinical Data: Demonstration of superior efficacy or safety profiles can sustain premium pricing.
- Regulatory Changes: Streamlined approval pathways or pricing reforms could influence market dynamics.
- Patent and Exclusivity Status: Patent cliffs accelerate price declines, whereas extended exclusivity sustains higher prices.
- Payer Policies: Reimbursement restrictions favor cost-effective competing therapies, reducing revenue for originators.
- Manufacturing Capacity: Scalability and supply chain robustness mitigate shortages and support steady pricing.
Strategic Implications for Stakeholders
For Manufacturers:
Proactively managing patent portfolios, optimizing biosimilar development timelines, and engaging early with payers are critical. Innovation leadership, such as formulations with improved administration or enhanced efficacy, can command premium prices longer.
For Payers and Providers:
Negotiating value-based contracts and fostering use of biosimilars contribute to cost containment. Education on biosimilar equivalence enhances acceptance and market share.
For Investors:
Pricing sustainability hinges on patent statuses, market penetration, and regulatory trajectories. Investment in pipeline diversification and biologic manufacturing capacity provides leverage.
Conclusion
NDC: 16714-0190 is positioned within a dynamic market characterized by high-value biologics, an evolving competitive landscape, and impending biosimilar entries. Price projections suggest a trajectory of initial premiums, followed by gradual reductions driven by biosimilar competition and market maturity. Stakeholders seeking to capitalize on this therapeutic niche should prioritize strategic positioning aligned with regulatory and reimbursement developments.
Key Takeaways
- The drug's market success depends on maintaining differentiation through clinical benefits and manufacturing excellence.
- Biosimilar competition is poised to exert significant downward pressure, typically ranging from 15-30% reductions over 3-5 years.
- Price strategies should adapt to evolving reimbursement policies, especially amid cost-containment efforts.
- Early engagement with payers and healthcare providers enhances market penetration and access.
- Continuous monitoring of regulatory updates and patent statuses is essential for accurate forecasting and strategic planning.
FAQs
1. How soon can biosimilars impact the price of NDC: 16714-0190?
Biosimilar entries typically influence pricing within 2-4 years post-approval, with initial discounts emerging as they gain market share.
2. What are the typical factors influencing pricing strategies for biologics like NDC: 16714-0190?
Manufacturing costs, clinical efficacy, market competition, patent status, rebate negotiations, and value-based reimbursement models are key factors.
3. Are there regional variations in the pricing projections for this drug?
Yes, prices vary significantly across regions due to differing regulatory, reimbursement, and market dynamics.
4. How does regulatory approval status influence future price projections?
Approval timelines and conditions can accelerate market entry and influence initial pricing, especially if orphan or expedited pathways are involved.
5. What role do healthcare policies play in the pricing and market penetration of such drugs?
Policies emphasizing cost-effectiveness and promoting biosimilar utilization tend to lower prices and improve competitive positioning.
References
[1] Global Market Insights. "Biologic Drugs Market Size and Growth." 2022.
More… ↓
